All In Biotech

Drug Trial Radar · NCT07660094

Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)

A Phase 3, Multicenter, Randomized, Controlled, Open-Label Clinical Trial of Aglatimagene Besadenovec (CAN-2409) Plus Prodrug and Pembrolizumab Versus Docetaxel for Stage IV Non-Squamous Non-Small Cell Lung Cancer Progressing on Pembrolizumab-based Treatment

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Jun 15, 2026

Primary completion

Oct 22, 2031

Study completion Oct 22, 2031

Sponsor

Lead sponsor
Candel Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial compares the effect of the combination of aglatimagene besadenovec and pembrolizumab versus standard of care docetaxel chemotherapy for the treatment of stage IV non-squamous, non-small cell lung cancer. Aglatimagene besadenovec is a replication-deficient adenoviral vector encoding the herpes simplex virus thymidine kinase (HSV-tk) gene. When combined with an oral prodrug (valacyclovir), injection of aglatimagene induces targeted tumor cell death and stimulates a systemic immune response. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving aglatimagene with pembrolizumab is more effective at treating patients with stage IV non-squamous, non-small cell lung cancer than standard chemotherapy.

Conditions

  • Non-squamous, Non-Small Cell Lung Cancer

Interventions

  • Aglatimagene BesadenovecBiological

    via intratumoral injections into lung or lymph nodes at two timepoints

  • ValacyclovirDrug

    Oral, for14 days following each aglatimagene besadenovec injection

  • PembrolizumabBiological

    every 3 weeks (Q3W) or every 6 weeks (Q6W)

  • DocetaxelDrug

    every 21 days with standard premedication

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: From date of randomization until date of death from any cause, assessed for a minimum of 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.